What does sCR1 stand for?

Soluble Complement Receptor 1 (molecular immunology)

This definition appears very rarely and is found in the following Acronym Finder categories:

Science, medicine, engineering, etc.

Other Resources:

<< Previous	Abbreviation Database Surfer		Next >>
Switch Configuration Register Switched Central Resource System Change Request System Concept Report System Concept Review System Conceptual Requirements System Control Room Systems Clock Reference (MPEG systems) Screened Coherent Potential Approximation Short Consensus Repeat 1		Soluble Form of Complement Receptor 2 (immunology term) Serial Control Register 3 Single-Channel Radio Relay and Retransmission System Scottish Countryside Rangers Association Sea Containers, Ltd Class A Stock (NYSE) Securities Contract Regulation Act (Indian law) Servicemembers Civil Relief Act of 2003 Shamokin Creek Restoration Alliance (Pennsylvania) Signal Corps Regimental Association Silicon Carbide Reinforced Aluminum

Samples in periodicals archive:

TP10, the product name for soluble Complement Receptor 1 (sCR1), is the first product candidate among a new class of therapeutics that AVANT is developing to inhibit inappropriate activation of complement.

AVANT Receives $6 Million Payment From Novartis

TP20 is a combined complement and selectin inhibitor that integrates soluble complement receptor 1 (sCR1) with the sLex (sialyl Lewis x) carbohydrate in a single molecule.

AVANT receives patent for use of its targeted, second generation ...

TP10, or soluble Complement Receptor 1 (sCR1), inhibitscomplement activation.

Novartis Exercises Option To Develop Avant's TP10

Avant's lead compound is TP10, soluble Complement Receptor 1 (sCR1), which inhibits complement activation.

EXPENSES REDUCED BY 40 PERCENT AVANT CUTS STAFF BY THIRD IN ...

TP10, the product name for soluble Complement Receptor 1 (sCR1), is the first product candidate among a new class of therapeutics T Cell Sciences is developing based on inhibiting complement activation.

Preliminary Phase I/II Study Results Demonstrate Clinical Efficacy Of ...

In July of this year, T Cell completed Phase I clinical trials which indicate soluble complement receptor 1, (product name TP10), is safe, and can inhibit complement activation in adult patients at risk for Adult Respiratory Distress Syndrome (ARDS).

T CELL SCIENCES, INC. ANNOUNCES OVER $6 MILLION PRIVATE PLACEMENT

Soluble complement receptor 1 (TP10) is a recombinantly produced soluble version of a naturally occurring protein that inhibits complement activation.

T CELL SCIENCES COMPLETES PHASE 1 CLINICAL TRIAL WITH TP10 IN ARDS

sCR1, soluble complement receptor 1, is T Cell Sciences' lead product candidate in its complement inhibitor pipeline.

T CELL SCIENCES RECEIVES ORPHAN DRUG DESIGNATION FOR sCR1 IN ARDS